CANCER JOURNAL - FRANCE, vol.11, no.2, pp.89-93, 1998 (SCI-Expanded)
Background - Empirical antibiotic therapy with a third-generation cephalosporin or a beta-lactam antibiotic which has broad antibacterial spectrum has been standard treatment in cancer patients with neutropenic fever. This prospective randomized trial was carried out to compare the efficacy of monotherapy (imipenem) with combination therapy (cefoperazone/sulbactam plus amikacin) in the empirical treatment of febrile neutropenia,